Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders. This cash dividend will be distributed on Monday, May 9, 2016, to shareholders of record as of Monday, May 2, 2016.
Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “This dividend declaration is a continuation of the Board’s plan to distribute a cash dividend of $0.05 per share per quarter. Of course, the board always has the discretion of discontinuing, increasing, or decreasing the dividend in accordance with the cash needs of the business.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a
premier developer of groundbreaking drug discovery and development
software, which is licensed to and used in the conduct of drug research
by major pharmaceutical and biotechnology companies worldwide. The
company is a global leader focused on improving the ways scientists use
knowledge and data to predict the properties and outcomes of
pharmaceutical and biotechnology agents. Our innovations in integrating
new and existing science in medicinal chemistry, computational
chemistry, pharmaceutical science, biology, and physiology into our
software have made us the leading software provider for physiologically
based pharmacokinetic modeling and simulation as well as a leading
provider of both preclinical and clinical pharmacometric consulting
services for regulatory submissions. For more information, visit our
website at www.simulations-plus.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160422005258/en/
Contacts:
Ms.
Renee Bouche, 661-723-7723
renee@simulations-plus.com
or
Hayden
IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com